<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639038</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300001699</org_study_id>
    <nct_id>NCT03639038</nct_id>
  </id_info>
  <brief_title>Tuberculosis Diagnosis by Flow Cytometry</brief_title>
  <official_title>Reagent Evaluation Plan: Tuberculosis Diagnosis by Flow Cytometry (Project Orion)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis and HIV continue to be major public health problems in resource constrained
      settings like Zambia. Zambia is among the top 30 highest burden countries globally. The major
      drivers of TB in the Africa region is the HIV epidemic. Inadequate TB diagnostic tools with
      failure to make a timely diagnosis and start appropriate treatment are the major impediments
      to TB control in Zambia and globally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project Orion is focused on utilizing Flow Cytometry Technology to screen and diagnose
      tuberculosis. There are two assays being tested under this Project:

        1. Activated TB assay for differentiation of latent and active TB infection using blood
           samples and

        2. Direct TB assay (DTA) for rapid detection and DST of Mycobacterium tuberculosis (Mtb)
           using sputum specimens.)
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI retired, study never opened.
  </why_stopped>
  <start_date type="Anticipated">September 30, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ATB assay for differentiation of latent and active TB infection using Blood samples</measure>
    <time_frame>The duration of this project is 9 months.</time_frame>
    <description>To evaluate the clinical utility of the test reagent(s) compared to diagnostic gold Standard: Culture and Xpert MTB/Rif along with clinical (empiric) diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DTB assay for rapid detection and drug sensitivity testing of Mtb using sputum specimens</measure>
    <time_frame>The duration of this project is 9 months.</time_frame>
    <description>To evaluate the clinical utility of the test reagent(s) compared to diagnostic gold Standard: Culture and Xpert MTB/Rif along with clinical (empiric) diagnosis</description>
  </primary_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Blood Assay Phase - 1</arm_group_label>
    <description>TB Positive / HIV Positive: 65 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood Assay Phase - 2</arm_group_label>
    <description>TB positive / HIV Negative: 65 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood Assay Phase - 3</arm_group_label>
    <description>TB positive and negative Paediatric: 30 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood Assay Phase - 4</arm_group_label>
    <description>TB Negative/HIV positive: 50 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood Assay Phase - 5</arm_group_label>
    <description>Healthy controls: 30 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sputum Collection Phase - 1</arm_group_label>
    <description>TB Positive: Xpert Rif sensitive: 100 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sputum Collection Phase - 2</arm_group_label>
    <description>TB Positive: Xpert Rif resistant: 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sputum Collection Phase - 3</arm_group_label>
    <description>TB Negative: Other chest: unknown number</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sputum Collection Phase - 4</arm_group_label>
    <description>TB Negative: Smear negative/Xpert negative: 20</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be selected on a first come, first serve basis at TB clinics in MOH
        District clinics in Lusaka. The participants will include both confirmed TB patients as
        well as presumptive TB patients. All participants should not have started anti-TB treatment
        (ATT) prior to enrollment or be less than five days from treatment start.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presumptive TB patients (patients recommended for tuberculosis diagnostic testing and
             not on ATT)

          -  Patients with multi-drug resistant TB (MDR-TB)

          -  Paediatric patients (&lt; 15 years old)

          -  Patients suspected of extra-pulmonary tuberculosis

          -  Patients with TB/HIV co-infection

        Exclusion Criteria:

          -  Unable/unwilling to sign Informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Monde Muyoyeta, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Infectious Disease Research in Zambia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Infectious Disease Research in Zambia (CIDRZ)</name>
      <address>
        <city>Lusaka</city>
        <zip>10102</zip>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>November 16, 2018</last_update_submitted>
  <last_update_submitted_qc>November 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Stewart Reid</investigator_full_name>
    <investigator_title>co-investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

